{"title":"加巴喷丁和普瑞巴林治疗屈光手术后疼痛的疗效:系统综述和荟萃分析。","authors":"Kai-Yang Chen, Hoi-Chun Chan, Li-Yun Wei, Chi-Ming Chan","doi":"10.1007/s10792-024-03300-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>For ophthalmic patients, eye discomfort is a major problem that requires efficient pain treatment techniques. Pregabalin and gabapentin have surfaced as viable treatments for post-refractive surgery pain. To manage pain after refractive surgery, gabapentin and pregabalin were evaluated in this systematic review and meta-analysis.</p><p><strong>Methodology: </strong>A thorough search of databases including PubMed, Embase, Cochrane Library, and CINAHL was performed until March 2024. Inclusion criteria were randomized controlled trials assessing pregabalin and/or gabapentin's effectiveness in treating pain post-PRK, LASIK, and LASEK surgeries.</p><p><strong>Results: </strong>Six studies met inclusion criteria, comprising a total of 391 patients undergoing various corneal surgeries. The meta-analysis revealed that pregabalin was significantly more effective than placebo in reducing pain on the first and second postoperative days (SMD day 1: -0.32, 95% CI -0.54, -0.09; SMD day 2: -0.55, 95% CI -0.85, -0.25), while gabapentin showed significant pain reduction on the second day only (SMD day 2: -0.42, 95% CI -0.71, -0.13). Combined analysis for both medications showed significant pain reduction on the first- and second-days post-surgery. No significant increase in adverse events was associated with either medication. Publication bias was minimal except for a slight asymmetry noted on day 1 effectiveness.</p><p><strong>Conclusion: </strong>Pregabalin and gabapentin are effective in reducing postoperative pain following refractive surgeries, with pregabalin showing a greater effect. Both medications are safe, with no significant increase in adverse events. Further research with standardized methodologies and long-term follow-up is recommended to optimize postoperative pain management in ocular surgeries.</p>","PeriodicalId":14473,"journal":{"name":"International Ophthalmology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of gabapentin and pregabalin for treatment of post refractive surgery pain: a systematic review and meta-analysis.\",\"authors\":\"Kai-Yang Chen, Hoi-Chun Chan, Li-Yun Wei, Chi-Ming Chan\",\"doi\":\"10.1007/s10792-024-03300-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>For ophthalmic patients, eye discomfort is a major problem that requires efficient pain treatment techniques. Pregabalin and gabapentin have surfaced as viable treatments for post-refractive surgery pain. To manage pain after refractive surgery, gabapentin and pregabalin were evaluated in this systematic review and meta-analysis.</p><p><strong>Methodology: </strong>A thorough search of databases including PubMed, Embase, Cochrane Library, and CINAHL was performed until March 2024. Inclusion criteria were randomized controlled trials assessing pregabalin and/or gabapentin's effectiveness in treating pain post-PRK, LASIK, and LASEK surgeries.</p><p><strong>Results: </strong>Six studies met inclusion criteria, comprising a total of 391 patients undergoing various corneal surgeries. The meta-analysis revealed that pregabalin was significantly more effective than placebo in reducing pain on the first and second postoperative days (SMD day 1: -0.32, 95% CI -0.54, -0.09; SMD day 2: -0.55, 95% CI -0.85, -0.25), while gabapentin showed significant pain reduction on the second day only (SMD day 2: -0.42, 95% CI -0.71, -0.13). Combined analysis for both medications showed significant pain reduction on the first- and second-days post-surgery. No significant increase in adverse events was associated with either medication. Publication bias was minimal except for a slight asymmetry noted on day 1 effectiveness.</p><p><strong>Conclusion: </strong>Pregabalin and gabapentin are effective in reducing postoperative pain following refractive surgeries, with pregabalin showing a greater effect. Both medications are safe, with no significant increase in adverse events. Further research with standardized methodologies and long-term follow-up is recommended to optimize postoperative pain management in ocular surgeries.</p>\",\"PeriodicalId\":14473,\"journal\":{\"name\":\"International Ophthalmology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10792-024-03300-9\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10792-024-03300-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
导言:对于眼科患者来说,眼部不适是一个主要问题,需要高效的疼痛治疗技术。普瑞巴林和加巴喷丁已成为治疗屈光手术后疼痛的可行方法。为了控制屈光手术后的疼痛,本系统综述和荟萃分析对加巴喷丁和普瑞巴林进行了评估:方法:在 2024 年 3 月之前,对包括 PubMed、Embase、Cochrane Library 和 CINAHL 在内的数据库进行了全面检索。纳入标准是评估普瑞巴林和/或加巴喷丁治疗PRK、LASIK和LASEK手术后疼痛有效性的随机对照试验:六项研究符合纳入标准,共有 391 名患者接受了各种角膜手术。荟萃分析显示,普瑞巴林在减轻术后第一天和第二天疼痛方面的效果明显优于安慰剂(SMD第一天:-0.32,95% CI -0.54,-0.09;SMD第二天:-0.55,95% CI -0.85,-0.25),而加巴喷丁仅在减轻第二天疼痛方面有显著效果(SMD第二天:-0.42,95% CI -0.71,-0.13)。对两种药物的综合分析表明,手术后第一天和第二天的疼痛均有明显减轻。两种药物的不良反应均无明显增加。除了第1天疗效略有不对称外,发表偏倚极小:普瑞巴林和加巴喷丁能有效减轻屈光手术后的疼痛,其中普瑞巴林的疗效更好。两种药物都很安全,不良反应没有明显增加。建议采用标准化方法和长期随访进行进一步研究,以优化眼科手术的术后疼痛管理。
Efficacy of gabapentin and pregabalin for treatment of post refractive surgery pain: a systematic review and meta-analysis.
Introduction: For ophthalmic patients, eye discomfort is a major problem that requires efficient pain treatment techniques. Pregabalin and gabapentin have surfaced as viable treatments for post-refractive surgery pain. To manage pain after refractive surgery, gabapentin and pregabalin were evaluated in this systematic review and meta-analysis.
Methodology: A thorough search of databases including PubMed, Embase, Cochrane Library, and CINAHL was performed until March 2024. Inclusion criteria were randomized controlled trials assessing pregabalin and/or gabapentin's effectiveness in treating pain post-PRK, LASIK, and LASEK surgeries.
Results: Six studies met inclusion criteria, comprising a total of 391 patients undergoing various corneal surgeries. The meta-analysis revealed that pregabalin was significantly more effective than placebo in reducing pain on the first and second postoperative days (SMD day 1: -0.32, 95% CI -0.54, -0.09; SMD day 2: -0.55, 95% CI -0.85, -0.25), while gabapentin showed significant pain reduction on the second day only (SMD day 2: -0.42, 95% CI -0.71, -0.13). Combined analysis for both medications showed significant pain reduction on the first- and second-days post-surgery. No significant increase in adverse events was associated with either medication. Publication bias was minimal except for a slight asymmetry noted on day 1 effectiveness.
Conclusion: Pregabalin and gabapentin are effective in reducing postoperative pain following refractive surgeries, with pregabalin showing a greater effect. Both medications are safe, with no significant increase in adverse events. Further research with standardized methodologies and long-term follow-up is recommended to optimize postoperative pain management in ocular surgeries.
期刊介绍:
International Ophthalmology provides the clinician with articles on all the relevant subspecialties of ophthalmology, with a broad international scope. The emphasis is on presentation of the latest clinical research in the field. In addition, the journal includes regular sections devoted to new developments in technologies, products, and techniques.